Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III

Excluding Veklury, Core Product Sales Grow

 
• By Alaric DeArment
Gilead reported its first quarter 2023 earnings on 27 April • Source: Shutterstock

More from Earnings

More from Business